Skip to content
DataLookout
Menu

NCT03911388

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 31 versions: 19 with changes below, 12 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Dec 31, 2027 Show 5 more changesShow less
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 1 of 6 entries
    • Study description revised
    • Site contacts updated at 1 of 3 sites
    • Collaborators: details revised at 1 of 2 entries
  2. Minor Site contacts updated at 1 of 3 sitesv30
  3. Minor Site details revised at 2 of 3 sitesv29
  4. Notable Eligibility criteria expanded, about 143 words
    • Secondary endpoints revised (6)
    • Study sites revised (3)
    v28
  5. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 3 of 3 sites
    v24
Show 13 earlier versionsHide 13 earlier versions
  1. Notable Lead sponsor: Gregory K. Friedman, MD to M.D. Anderson Cancer Centerv22
  2. Notable Primary completion date: Sep 1, 2025 to Sep 1, 2026
    • Study completion date: Sep 1, 2026 to Sep 1, 2027
    v21
  3. Notable Enrollment target: 15 to 24
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 1 to 3
    • Study description expanded, about 12 words
    v20
  4. Notable Primary completion date: Sep 1, 2024 to Sep 1, 2025
    • Study completion date: Sep 1, 2025 to Sep 1, 2026
    v19
  5. Minor Collaborators: 3 to 2v18
  6. Notable Eligibility criteria expanded, about 39 wordsv17
  7. Notable Lead sponsor: University of Alabama at Birmingham to Gregory K. Friedman, MDv16
  8. Minor Collaborators expanded, about 11 wordsv15
  9. Notable Primary completion date: Sep 1, 2023 to Sep 1, 2024
    • Study completion date: Sep 1, 2024 to Sep 1, 2025
    • Site contact updated
    v13
  10. Notable Primary completion date: Sep 1, 2022 to Sep 1, 2023
    • Eligibility criteria shortened, about 17 words
    • Study completion date: Sep 1, 2023 to Sep 1, 2024
    v6
  11. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2019 to Sep 12, 2019
    • Site details revised
    v4
  12. Notable Start date: Jul 1, 2019 to Sep 1, 2019
    • Primary completion date: Jul 1, 2022 to Sep 1, 2022
    • Study completion date: Jul 1, 2023 to Sep 1, 2023
    v3
  13. Minor Secondary endpoints: details revised at 1 of 6 entries
    • Study title shortened, about 5 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse Events
Timeframe: Baseline to 15 years

Secondary (6)

Immunologic Response
Virologic Shedding
Progression Free Survival
Overall Survival
Change in Performance Score (Ability to Perform Normal Activities)
Show 1 moreShow less
Quality of Life (optional)

Arms and interventions

HSV G207Experimental

Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.

Biologicals: G207

Sites

3 sites in 1 country